Search Results 7311-7320 of 26472 for oral

  1. Publications - Yunhong Shu, Ph.D. - Mayo Clinic

    ... Oral Exam. Med Phys. 2012 Jun; 39 (6Part27):3954. View PubMed; Kalamkar DD, Trzasko JD, Sridharan S, Smelyanskiy M, Kim D, Manduca A, Shu Y, Bernstein MA ...

  2. Spinal cord tumor - Doctors and departments - Mayo Clinic

    ... Oral and throat cancer, Adenocarcinoma, Laryngeal cancer, Carotid body tumor, Tongue base cancer, Mouth tumor, Salivary gland cancer, Parotid cancer ...

  3. Throat cancer - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Oropharynx Cancer Clinic in Minnesota · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Plastic ...

  4. Dantrolene (intravenous route) - Side effects & uses - Mayo Clinic

    Precautions. Your doctor will only give you a few doses of this medicine until your condition improves, and then you will be switched to an oral medicine ...

  5. A Study to Assess the Effectiveness, Safety and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 Inflammation - Mayo Clinic

    ... oral) and/or antibiotics. One of the two required moderate exacerbations has to require the use of systemic corticosteroids. **Severe exacerbations are ...

  6. Hematology - Clinical trials

    This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL. The trial will be ...

  7. Intensity-Modulated Radiation Therapy and Paclitaxel with or without Pazopanib Hydrochloride in Treating Patients with Anaplastic Thyroid Cancer - Mayo Clinic

    Patients with any condition that may impair the ability to absorb oral medications/investigational product including: Prior surgical procedures affecting ...

  8. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy - Mayo Clinic

    Immunosuppressive or immunomodulating treatment, including chronic oral or IV steroids, must be discontinued at least 4 weeks prior to screening. History of ...

  9. Cardiovascular Medicine - Clinical trials - Mayo Clinic

    ... (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition ...

  10. A Study to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly - Mayo Clinic

    Currently receiving other treatments known to affect GH or IGF-1 concentration (including oral estrogens for e.g. contraception or replacement treatment in ...